New cancer Drug's interactions tested in healthy women

NCT ID NCT05444556

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 study looked at how imlunestrant, a potential cancer drug, affects the body's handling of other medications like repaglinide, omeprazole, and dextromethorphan. It also tested how quinidine changes imlunestrant levels. 113 healthy women of non-childbearing potential took part to measure drug levels and safety. The goal is to understand possible drug interactions before imlunestrant is used in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imlunestrant
What this could lead to: If successful, this study will help doctors understand how imlunestrant interacts with other medications, guiding safer use in future patients.
What could go wrong: This is an early-phase study in healthy volunteers, not patients. It focuses on drug interactions, not treatment effects, so results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Locations

Altasciences Clinical Los Angeles, Inc

Cypress, California, 90630, United States
ICON Early Phase Services

San Antonio, Texas, 78209, United States
Qps-Mra, Llc

South Miami, Florida, 33143-4875, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.